Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression
Ankylosing spondylitis (AS) is one of the major inflammatory diseases that affect the vertebral column and joints. The first-line drugs for the treatment of this disease are now nonsteroidal anti-inflammatory drugs (NSAIDs) that not only reduce painful sensations and rigidity, but also retard the ra...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2012-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040622864400384 |
|---|---|
| author | Yulia Leonidovna Korsakova |
| author_facet | Yulia Leonidovna Korsakova |
| author_sort | Yulia Leonidovna Korsakova |
| collection | DOAJ |
| description | Ankylosing spondylitis (AS) is one of the major inflammatory diseases that affect the vertebral column and joints. The first-line drugs for the treatment of this disease are now nonsteroidal anti-inflammatory drugs (NSAIDs) that not only reduce painful sensations and rigidity, but also retard the radiological progression of AS. Celecoxib is one of the effective and safe NDAIDs that are promising for the treatment of AS. |
| format | Article |
| id | doaj-art-0d497dc4ac68404d8f9dbc3439d0847e |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2012-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-0d497dc4ac68404d8f9dbc3439d0847e2025-08-20T02:56:02ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2012-09-0163747710.14412/1996-7012-2012-7521742Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progressionYulia Leonidovna KorsakovaAnkylosing spondylitis (AS) is one of the major inflammatory diseases that affect the vertebral column and joints. The first-line drugs for the treatment of this disease are now nonsteroidal anti-inflammatory drugs (NSAIDs) that not only reduce painful sensations and rigidity, but also retard the radiological progression of AS. Celecoxib is one of the effective and safe NDAIDs that are promising for the treatment of AS.https://mrj.ima-press.net/mrj/article/view/437ankylosing spondylitisnonsteroidal anti-inflammatory drugscelexoxib |
| spellingShingle | Yulia Leonidovna Korsakova Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression Современная ревматология ankylosing spondylitis nonsteroidal anti-inflammatory drugs celexoxib |
| title | Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression |
| title_full | Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression |
| title_fullStr | Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression |
| title_full_unstemmed | Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression |
| title_short | Prospects for the use of celecoxib in patients with ankylosing spondylitis: impact on retarding disease progression |
| title_sort | prospects for the use of celecoxib in patients with ankylosing spondylitis impact on retarding disease progression |
| topic | ankylosing spondylitis nonsteroidal anti-inflammatory drugs celexoxib |
| url | https://mrj.ima-press.net/mrj/article/view/437 |
| work_keys_str_mv | AT yulialeonidovnakorsakova prospectsfortheuseofcelecoxibinpatientswithankylosingspondylitisimpactonretardingdiseaseprogression |